Katleen Verleysen
CEO

miDiagnostics is developing a silicon nanofluidic processor that enables ultra-fast PCR testing with lab-quality sensitivity and specificity, requiring only a small sample size. This technology decentralizes diagnostic testing, providing rapid results at the point of care, which addresses delays and inefficiencies associated with traditional centralized laboratory testing.
Raised to date
$216.2MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CEO
Traditional diagnostic testing often relies on centralized laboratories, leading to delays in obtaining results and potentially impacting patient management. Current point-of-care alternatives may sacrifice accuracy for speed or lack the ease of use required for decentralized settings.
miDiagnostics is developing a diagnostic platform that combines accuracy, speed, and ease of use by decentralizing molecular diagnostic testing. Their solution utilizes a silicon nanofluidic processor for ultra-fast PCR testing, achieving lab-quality sensitivity and specificity with minimal sample volume. The system comprises a PCR card containing a silicon chip with a micro-channel network, a portable reader with thermal and optical processing capabilities, and software for data analysis and connectivity. This integrated approach enables rapid and reliable results at the point of care, facilitating timely clinical decision-making.
The primary target audience includes healthcare workers and clinicians seeking rapid, accurate diagnostic tools for point-of-care testing, as well as biopharmaceutical companies requiring sterility testing and quality control solutions.